[1]隰子涵,邵国良.基于MRI影像组学预测肝癌经导管动脉化疗栓塞术后疗效研究进展[J].介入放射学杂志,2024,33(01):90-94.
　XI Zihan,SHAO Guoliang..Research progress in MRI-based radiomics for predicting the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):90-94.
点击复制

基于MRI影像组学预测肝癌经导管动脉化疗栓塞术后疗效研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年01
页码:
90-94
栏目:
综述
出版日期:
2024-01-31

文章信息/Info

Title:
Research progress in MRI-based radiomics for predicting the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma
作者:
隰子涵;  邵国良
Author(s):
XI Zihan;  SHAO Guoliang.
Wenzhou Medical University； Department of Interventional Therapy， Zhejiang Provincial Cancer Hospital， Wenzhou， Zhejiang Province 325035， China
关键词:
【关键词】 肝癌;  经导管动脉化疗栓塞术;  影像组学;  疗效预测
文献标志码:
A
摘要:
【摘要】 肝癌是全球第五大常见恶性肿瘤，临床上有起病隐匿、致死率高等特点。经导管动脉化疗栓塞术（TACE）作为中晚期肝癌患者首选治疗方法，具有降低肿瘤负荷、减轻患者痛苦诸多优势，但受益人群选择仍具挑战性。因此，TACE后疗效预测至关重要。目前有临床检验学、影像学、基因分子学等多种方法可用于预测TACE后疗效。影像学预测具有直观、可解释性强等优点，MRI功能成像序列更能显示病灶细节。影像组学作为新兴领域，可通过量化肿瘤表型变异起到补充甚至取代肿瘤活检的作用。本综述回顾影像组学与肝癌TACE后疗效预测相关研究，评估MRI影像组学是否可作为肝癌TACE后疗效的有效且可重复的预测方法。

参考文献/References:

［1］ Sung H， Ferlay J， Siegel RL， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209-249.
［2］ Zhou M， Wang H， Zeng X， et al. Mortality， morbidity， and risk factors in China and its provinces， 1990-2017： a systematic analysis for the Global Burden of Disease Study 2017［J］. Lancet， 2019， 394： 1145-1158.
［3］ 国家卫生健康委办公厅.原发性肝癌诊疗指南（2022年版）［J］. 临床肝胆病杂， 2022， 13 ：549-570 .
［4］ Wei G，Yang J. Advances in the treatment of hepatocellular carcinoma using drug-eluting beads［J］. J Interv Med， 2020， 3： 122-127.
［5］ Peng CW， Teng W， Lui KW， et al. Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma［J］. Am J Cancer Res， 2021， 11： 4956-4965.
［6］ Galle PR， Tovoli F， Foerster F， et al. The treatment of intermediate stage tumours beyond TACE： from surgery to systemic therapy［J］. J Hepatol， 2017， 67： 173-183.
［7］ Zanfardino M， Franzese M， Pane K， et al. Bringing radiomics into a multi-omics framework for a comprehensive genotype-phenotype characterization of oncological diseases［J］. J Transl Med， 2019， 17： 337.
［8］ Mishra G， Dev A， Paul E， et al. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation［J］. BMC Cancer， 2020， 20： 483.
［9］ Zhao YM， Wang L， Dai Z， et al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma［J］. Int J Cancer， 2011， 129： 2463-2472.
［10］ Ke Q， Xiang F， Xiao CH， et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization［J］. BMC Cancer， 2021， 21： 1117.
［11］ Ho SY， Hsu CY， Liu PH， et al. Albumin-bilirubin（ALBI） grade-based nomogram for patients with hepatocellular carcinoma undergoing transarterial chemoembolization［J］. Dig Dis Sci， 2021， 66： 1730-1738.
［12］ Wang Q， Xia D， Bai W， et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma： a multicentre observational study［J］. J Hepatol， 2019， 70： 893-903.
［13］ Wei J， Jiang H， Gu D， et al. Radiomics in liver diseases： current progress and future opportunities［J］. Liver Int， 2020， 40： 2050-2063.
［14］ Wakabayashi T， Ouhmich F， Gonzalez-Cabrera C， et al. Radiomics in hepatocellular carcinoma： a quantitative review［J］. Hepatol Int， 2019， 13： 546-559.
［15］ Avanzo M， Wei L， Stancanello J， et al. Machine and deep learning methods for radiomics［J］. Med Phys， 2020， 47： e185-e202.
［16］ 陈 霞，李文柱，陈旺生，等． 多模态MRI术前诊断肝细胞癌微血管浸润应用进展［J］． 中国医学影像技术， 2019， 35：294-297．
［17］ Lee SM， Kim HS， Lee S， et al. Emerging role of 18F-fluorodeo?蛳xyglucose positron emission tomography for guiding management of hepatocellular carcinoma［J］. World J Gastroenterol， 2019， 25： 1289-1306.
［18］ Song W， Yu X， Guo D， et al. MRI-based radiomics： associations with the recurrence-free survival of patients with hepatocellular carcinoma treated with conventional transcatheter arterial chemo?蛳embolization［J］. J Magn Reson Imaging， 2020， 52： 461-473.
［19］ Ivanics T， Salinas-Miranda E， Abreu P， et al. A pre-TACE radiomics model to predict HCC progression and recurrence in liver transplantation： a pilot study on a novel biomarker［J］. Transplantation， 2021， 105： 2435-2444.
［20］ 孙跃军，白洪林，王 栋，等． 术前T2磁共振影像组学在预测介入治疗大肝癌近期疗效的研究［J］． 介入放射学杂志， 2019，28：1036-1041．
［21］ Xu X， Zhang HL， Liu QP， et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma［J］. J Hepatol， 2019， 70： 1133-1144.
［22］ 张利文，方梦捷，臧亚丽，等． 影像组学的发展与应用［J］． 中华放射学杂志， 2017， 51：75-77．
［23］ Panth KM， Leijenaar RTH， Carvalho S， et al. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells［J］. Radiother Oncol， 2015， 116： 462-466.
［24］ Sun Y， Bai H， Xia W， et al. Predicting the outcome of transcatheter arterial embolization therapy for unresectable hepatocellular carcinoma based on radiomics of preoperative multiparameter MRI［J］. J Magn Reson Imaging， 2020， 52： 1083-1090.
［25］ Liu QP， Yang KL， Xu X， et al. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization： a two-center collaborative study［J］. Abdom Radiol（NY）， 2022， 47： 651- 663.
［26］ Luo J， Huang Z， Wang M， et al. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy［J］. BMC Gastroenterol， 2022， 22： 108.
［27］ Kong C， Zhao Z， Chen W， et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE［J］. Eur Radiol， 2021， 31： 7500-7511.
［28］ Kuang Y， Li R， Jia P， et al. MRI-based radiomics： nomograms predicting the short-term response after transcatheter arterial chemoembolization（TACE） in hepatocellular carcinoma patients with diameter less than 5 cm［J］. Abdom Radiol（NY）， 2021， 46： 3772-3789.
［29］ Da-Ano R， Visvikis D， Hatt M. Harmonization strategies for multicenter radiomics investigations［J］. Phys Med Biol， 2020， 65： 24TR02.
［30］ Boellaard R， Delgado-Bolton R， Oyen WJ， et al. FDG PET/CT： EANM procedure guidelines for tumour imaging： version 2.0［J］. Eur J Nucl Med Mol Imaging， 2015， 42： 328-354.
［31］ Frangi AF， Tsaftaris SA， Prince JL. Simulation and synthesis in medical imaging［J］. IEEE Trans Med Imaging， 2018， 37： 673-679.
［32］ Lucia F， Visvikis D， Vallieres M， et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemora?蛳diotherapy［J］. Eur J Nucl Med Mol Imaging， 2019， 46： 864-877.
［33］ Chen Y， Qin X， Long L， et al. Diagnostic value of Gd-EOB-DTPA-Enhanced MRI for the expression of Ki67 and microvascular density in hepatocellular carcinoma［J］. J Magn Reson Imaging， 2020， 51： 1755-1763.
［34］ Meng XP， Wang YC， Zhou JY， et al. Comparison of MRI and CT for the prediction of microvascular invasion in solitary hepatocellular carcinoma based on a non-radiomics and radiomics method： which imaging modality is better?［J］. J Magn Reson Imaging， 2021， 54： 526-536.

相似文献/References:

[1]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(01):348.
[2]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(01):322.
[3]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(01):621.
[4]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(01):968.
[5]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(01):1010.
[6]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(01):75.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(01):682.
[8]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(01):1035.
[9]徐 阳,臧 爽,陈路锋,等.Logistic回归及ROC曲线综合评价血生化指标对肝癌TACE术后发热的预测价值 [J].介入放射学杂志,2013,(06):513.
　XU Yang,ZANG Shuang,CHEN Lu? feng,et al. Combination evaluation of plasma biochemical indexes with Logistic regression and ROC analysis in predicting hyperthermia after transcatheter hepatic arterial chemoembolization for liver cancer[J].journal interventional radiology,2013,(01):513.
[10]彭国文,李晓群. 射频消融及组合方案治疗特殊/高危部位肝癌的中远期疗效[J].介入放射学杂志,2013,(06):525.
　PENG Guo? wen,LI Xiao? qun.. The mid?蛳 to?蛳 long term efficacy of radiofrequency ablation together with combination regimen for the treatment of hepatic carcinomas located at special or high?蛳 risk regions[J].journal interventional radiology,2013,(01):525.
[11]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(01):78.
[12]李 征,米登海,杨克虎,等.经动脉化疗栓塞联合微波消融治疗肝癌有效性和安全性的系统评价[J].介入放射学杂志,2015,(11):957.
　LI Zheng,MI Deng- hai,YANG Ke- hu,et al.Effectiveness and safety of TACE combined with MWA for primary hepatic cancer： a systematic review[J].journal interventional radiology,2015,(01):957.
[13]马婧嶔,颜志平.肝癌介入治疗进一步思考[J].介入放射学杂志,2019,28(06):507.
　MA Jingqin,YAN Zhiping..Further consideration on interventional therapy of liver cancer[J].journal interventional radiology,2019,28(01):507.
[14]侯昌龙,熊柏柱,许 军,等.经颈静脉肝内门体分流术治疗肝癌合并门静脉高压的临床价值 [J].介入放射学杂志,2023,32(04):320.
　HOU Changlong,XIONG Baizhu,XU Jun,et al.The clinical value of transjugular intrahepatic portosystemic shunt in the treatment of hepatocellular carcinoma complicated by portal hypertension[J].journal interventional radiology,2023,32(01):320.

备注/Memo

备注/Memo:
（收稿日期：2022-12-18）
（本文编辑：谷 珂）
更新日期/Last Update: 2024-01-30